SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Vascular Biogenics Ltd. (VBLT)

VBLT RSS Feed
Add VBLT Price Alert      Hide Sticky   Hide Intro
Moderator: gr8db8
Search This Board: 
Last Post: 2/23/2017 6:08:34 PM - Followers: 30 - Board type: Free - Posts Today: 0

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its clinical pipeline is based on two platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. As of June 6, 2014, it has developed two programs based on these platforms an oncology program and an anti-inflammatory program. Its lead product candidate from its oncology program, VB-111, is a gene-based biologic that is initially developing for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. The Company has also received orphan drug designation in both the United States and Europe. The Company’s oncology program is based on its Vascular Targeting System (VTS), platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. http://www.vblrx.com
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VBLT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
VBLT News: Report of Foreign Issuer (6-k) 02/21/2017 07:28:06 AM
VBLT News: VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer 02/21/2017 07:00:00 AM
VBLT News: VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference 02/06/2017 08:00:00 AM
VBLT News: VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target 01/31/2017 04:01:00 PM
VBLT News: Report of Foreign Issuer (6-k) 01/09/2017 09:02:37 AM
PostSubject
#553  Sticky Note Update letter to shareholders this morning from our mjw007 01/09/17 10:11:48 AM
#636   Yes, '16. If you look carefully at the davidal66 02/23/17 06:08:34 PM
#635   Did you mean to say "recurrence sometime around wcopeland 02/23/17 12:55:01 PM
#634   Found another interesting case on Facebook regarding VB-111. davidal66 02/23/17 12:26:48 PM
#633   I think we are venturing onto something else Prana1 02/23/17 12:09:45 AM
#632   Personal doctor of a patient can't recommend his Oren1976 02/22/17 11:39:30 PM
#631   I think that even if that was the Prana1 02/22/17 11:06:49 PM
#630   Vb111 showed full response in couple of cases Oren1976 02/22/17 10:58:52 PM
#629   I am sorry. But where did you get Prana1 02/22/17 10:14:25 PM
#628   Hear u I am surprised the market did mjw007 02/22/17 08:34:17 PM
#627   Vbl should sell 2 billion per quarter once Oren1976 02/22/17 03:39:46 AM
#626   The market will understand after the big huge Oren1976 02/22/17 02:48:45 AM
#625   Those are all keys stats (granted with a gr8db8 02/22/17 02:07:10 AM
#624   The most interesting part of today's press release davidal66 02/21/17 06:55:23 PM
#623   Sorry, I just don't follow your logic on davidal66 02/18/17 06:22:06 PM
#622   I see now but still it doesn't refute Oren1976 02/18/17 04:43:04 PM
#621   The limited disease cohort with VB-111 as mono davidal66 02/18/17 04:16:38 PM
#620   Looking at the phase 2 results may I Oren1976 02/18/17 03:43:04 PM
#619   Thank u I will check the phase 2 Oren1976 02/18/17 03:33:07 PM
#618   If you look at the phase II VB-111 davidal66 02/18/17 12:53:22 PM
#617   People with rgbm stopping avastin find the tumor Oren1976 02/17/17 11:09:47 PM
#616   Also they will be having an R and davidal66 02/13/17 10:51:44 PM
#615   Good to hear confirmation on upcoming events: gr8db8 02/13/17 03:50:19 PM
#614   Oren, you were right. Good talk, but talk davidal66 02/13/17 02:10:08 PM
#613   http://www.abstractsonline.com/pp8/#!/4292/presentation/3559 davidal66 02/10/17 04:16:01 PM
#612   davidal66 ... Q4 call is in March. gr8db8 02/10/17 12:31:01 AM
#611   Not sure, but u could be right. davidal66 02/10/17 12:29:50 AM
#610   Guessing ... gr8db8 02/10/17 12:24:26 AM
#609   The speaker is not dror . He will Oren1976 02/09/17 11:46:51 PM
#608   Not so sure... davidal66 02/09/17 11:36:56 PM
#607   There won't be anything new in this confrence Oren1976 02/09/17 07:19:10 PM
#606   You feel the upcoming conference presentation is the mjw007 02/09/17 01:10:43 PM
#605   FEB 13-14. Lucky40 02/09/17 12:11:51 PM
#604   Gen 13-14 Lucky40 02/09/17 12:11:23 PM
#603   VBLT making a nice little run here Decent volume mjw007 02/09/17 12:10:51 PM
#602   I believe you can watch it live after gr8db8 02/08/17 04:04:33 PM
#601   THANKS Smokey John 02/08/17 03:32:52 PM
#600   It should be archived on their website a davidal66 02/08/17 03:03:21 PM
#599   ANY WAY WE CAN ACCESS THE CONFERENCE CALL? Smokey John 02/08/17 02:40:18 PM
#598   It's next week: https://ceo17.eventsbio.com/connect/search.ww gr8db8 02/07/17 12:50:24 PM
#597   When is the conference call? Shouldn't it be davidal66 02/07/17 12:10:27 PM
#596   Perhaps the January presentation will be used: http://ir.vblrx.com/phoenix.zhtml gr8db8 02/07/17 11:25:02 AM
#595   My guess they release full data thyroid and Oren1976 02/06/17 06:23:34 PM
#594   I think he will detail more about VB-600 davidal66 02/06/17 03:27:45 PM
#593   Any thoughts on what will be covered next week? gr8db8 02/06/17 12:20:56 PM
#592   That makes sense, davidal66. The recent release on gr8db8 02/02/17 03:45:36 PM
#591   I'm not sure. I'm not sure a checkpoint davidal66 02/02/17 02:58:27 PM
#590   Will they confirm this on the next call? gr8db8 02/02/17 11:36:18 AM
#589   The cash from last dilution is for a Oren1976 02/02/17 03:21:41 AM
#588   Agree! Will learn more about VB-600 and also gr8db8 02/01/17 01:18:41 PM
#587   They have been very cryptic on VB600. I'm davidal66 02/01/17 12:59:11 PM
PostSubject